UNDERGRADUATE RESEARCH IN NATURAL AND CLINICAL SCIENCE AND TECHNOLOGY (URNCST) JOURNAL
Read more URNCST Journal articles and submit your own today at: https://www.urncst.com

ENCYCLOPEDIA ENTRY OPEN ACCESS

Schizophrenia

Marjan Navidpour, BA Student*

Department of Psychology, University of California Los Angeles, Los Angeles, California, United States, 90095

*Corresponding Author: marjan23@g.ucla.edu

Abstract

Schizophrenia is a complex and multifaceted psychotic disorder that affects millions of people worldwide. It is characterized by positive symptoms, such as hallucinations and delusions, negative symptoms, including avolition and anhedonia, and persistent cognitive impairments that significantly disrupt daily functioning. The disorder typically emerges in early adulthood, with distinct variations in symptom presentation and onset age between males and females. Historically misinterpreted as madness or spiritual disturbance, schizophrenia is now recognized as a neurodevelopmental disorder with both genetic and environmental contributions. The disorder carries a high burden on affected individuals, caregivers, and healthcare systems, particularly due to its treatment resistance and association with premature mortality. The current understanding of schizophrenia reflects multifactorial origins. Genetic studies highlight a strong heritable component, supported by twin concordance rates and genome-wide association studies. Neuroimaging reveals structural brain differences, including reduced gray and white matter volumes and enlarged lateral ventricles, which may correlate with symptom severity. Environmental factors such as prenatal complications, childhood adversity, psychosocial stressors, and adolescent substance use contribute to the disorder's onset and progression. Diagnosis relies on criteria set forth by the DSM-5, which emphasizes symptom duration and functional impairment. Treatments include pharmacological interventions and psychosocial therapies such as cognitive behavioral therapy, social skills training, and family psychoeducation. Despite available interventions, approximately one-third of individuals with schizophrenia are resistant to standard treatment, prompting the use of medications like clozapine and exploration of adjunctive methods such as electroconvulsive therapy. Recent research focuses on improving outcomes for negative and cognitive symptoms through novel medications targeting various neurotransmitters, neuroinflammation, and cholinergic pathways. Lifestyle-based interventions, including exercise and the role of the microbiome, are also gaining traction as complementary treatment strategies.

Keywords: schizophrenia; psychotic; positive symptoms; negative symptoms; cognitive impairment; ECT

Introduction and Definition

"Schizophrenia, a serious mental illness, affects 1% of the global population and is marked by hallucinations, delusions, disorganized speech, grossly disorganized behavior, and negative signs and symptoms such as reduced emotional expression, avolition, and cognitive impairment" [1].

Schizophrenia is a complex psychotic disorder that affects millions of people around the world. First recognized as a distinct mental illness in the early 20th century, schizophrenia has been the subject of extensive research aimed at understanding its origins, progression, and treatment. Historically, it was thought to be caused by a range of environmental and biological factors, reflecting early psychiatric theories that linked mental illness to social stressors, childhood trauma, and physiological imbalances [2]. Modern research emphasizes a combination of genetic and neurobiological factors in its etiology. Schizophrenia is often associated with a profound impact on individuals' quality of life, creating challenges for patients, caregivers, and healthcare systems. Caregivers frequently experience emotional distress and financial strain due to the chronic and relapsing nature of the illness, while healthcare systems face substantial resource demands due to the necessity of long-term care. A combination of treatment types yields the best outcomes, and early treatment is most beneficial in managing symptoms and improving long-term outcomes.

Schizophrenia is multifaceted, with symptoms classified into positive (hallucinations, delusions, etc.), negative (social withdrawal, lack of motivation), and cognitive impairments (memory, attention). The onset typically occurs in early adulthood, with varying degrees of severity. The pathophysiology of schizophrenia involves abnormalities in brain structure and function, particularly in regions related to cognition and emotional regulation. Early research suggests that an imbalance in the neurotransmitter dopamine plays a

pivotal role in the manifestation of symptoms. Current research continues to explore genetic predispositions and environmental triggers, aiming to refine early detection methods and develop targeted treatments. Recent findings focus on advancements in neuroimaging techniques, which offer insights into the brain's altered structures in schizophrenia patients. New treatments, including novel antipsychotic medications and lifestyle changes, show promise in improving patient outcomes. However, there is no cure, and challenges remain in addressing the cognitive and negative symptoms that impair functioning. Schizophrenia can make it difficult to participate in daily tasks or activities and have poor long-term outcomes [3].

Body

History

The conceptualization of schizophrenia has evolved significantly over the centuries. Early descriptions of psychotic phenomena—such as auditory hallucinations and delusional behavior—appear in ancient medical and religious texts, often framed as episodes of madness or spiritual possession. However, the formal classification of schizophrenia as a distinct psychiatric disorder emerged in the late 19th and early 20th centuries. In 1893, German psychiatrist Emil Kraepelin introduced the term *dementia praecox* to describe a pattern of early-onset, chronic mental illness characterized by progressive cognitive and behavioral deterioration. His observations continue to influence our current understanding of psychosis [4]. It wasn't until 1911 that Swiss psychiatrist Eugen Bleuler redefined Kraepelin's concept and coined the term "schizophrenia", emphasizing a "split" between mental functions [5]. Bleuler introduced the foundational distinction between "positive" symptoms (e.g., hallucinations and delusions) and "negative" symptoms (e.g., affective flattening and avolition). Over the decades, diagnostic criteria, treatment approaches, and models of care have evolved, enhancing diagnostic reliability and patient outcomes.

Prevalence

Schizophrenia affects about 24 million people, or 0.33–0.75% of the global population. Prevalence rates vary across geographic, socioeconomic, and demographic factors, with notable differences by gender [6]. Geographically, higher prevalence rates are reported in urbanized and industrialized regions as well as countries with higher socioeconomic status [7]. Onset typically occurs in early adulthood, in males between the ages of 21 and 25, and females between 25 and 30. Symptom presentation also differs with gender, as males are more likely to exhibit prominent negative symptoms, while females more often present with affective symptoms, including mood disturbances. Additionally, females tend to perform better on cognitive tasks, particularly those measuring executive functioning [8].

Schizophrenia is associated with a significant increase in premature mortality, with individuals diagnosed with the disorder being two to three times more likely to die early compared to the general population [9]. On average, life expectancy is reduced by 15 to 20 years. This risk is attributed to co-occurring physical illnesses, such as metabolic diseases, as well as social isolation, poverty, and barriers to accessing healthcare. Early intervention and comprehensive treatment are essential for mitigating these disparities and improving long-term outcomes [10].

Causes

Extensive research has been dedicated to exploring the multifactorial causes of schizophrenia. The disorder is widely understood through the diathesis-stress model, which explains psychiatric conditions as the result of both dispositional biological factors (diathesis) and environmental stressors [11].

Dispositional Biological Factors

Genetically, schizophrenia is among the most heritable psychiatric disorders, with twin and family studies indicating a heritability estimate of approximately 80%. Monozygotic twins show concordance rates of up to 50%, significantly higher than those observed in the general population, underscoring a strong genetic component [12]. Genome-wide association studies have identified numerous variants in genes related to dopamine signaling, synaptic function, and immune processes [13]. Neuroimaging studies have revealed consistent structural brain abnormalities in individuals with schizophrenia, including reduced gray and white matter density [14]. These changes are thought to reflect neurodevelopmental alterations that may precede symptom onset and progress throughout the illness. Enlarged lateral ventricles are another neuroanatomical difference observed in individuals with schizophrenia compared to healthy controls and are believed to correlate with the severity of psychotic symptoms [15].

Environmental Factors

However, genetic and neurobiological factors alone are insufficient to fully explain the onset of schizophrenia. Prenatal complications—such as maternal infections, malnutrition, and obstetric hypoxia—have been linked to an elevated risk of developing the disorder [16]. Childhood adversity, including trauma or neglect, and psychosocial stressors—such as urban upbringing, migration, and experiences of discrimination—have also been associated with heightened risk, particularly among ethnic and racial minorities [17]. In addition, substance use—particularly cannabis and psychedelic drugs during adolescence—has been identified as a significant risk factor for developing psychosis, particularly in genetically vulnerable individuals [18]. These findings support the notion that schizophrenia is not caused by a single factor, but by the cumulative effect of multiple biological and environmental disruptions.

Diagnostic Criteria

Schizophrenia is diagnosed according to criteria in the *Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5)*. Two or more of the following symptoms must be present for a significant portion of time during one month, with continuous signs of disturbance persisting for at least six months: delusions, hallucinations, disorganized speech, grossly disorganized or catatonic behavior, and negative symptoms. At least one of the symptoms must be delusions, hallucinations, or disorganized speech. These symptoms must cause significant impairment in social, occupational, or self-care functioning, and the DSM-5 also requires that other potential causes—such as mood disorders with psychotic features or substance-induced psychosis—be ruled out prior to diagnosis [19].

Schizophrenia is characterized by three primary symptom domains: positive symptoms, negative symptoms, and cognitive impairments. Positive symptoms refer to experiences that distort normal perception and thinking, such as hallucinations (most commonly auditory) and delusions (false beliefs not grounded in reality). In contrast, negative symptoms are the absence or reduction of normal emotional and behavioral functions, such as avolition (a lack of motivation) or anhedonia (a reduced ability to experience pleasure). Cognitive symptoms, which can overlap with negative features, are among the most persistent and treatment-resistant aspects of this disorder. They may include disorganized thinking, impaired attention, deficits in working memory, and executive dysfunction. These cognitive disturbances significantly contribute to the functional disability observed in schizophrenia and are a major target of ongoing research and intervention efforts [20].

Treatment

The treatment for schizophrenia requires a multimodal approach, combining pharmacological interventions, psychotherapy, and psychosocial support. The primary goal of treatment is to reduce symptom severity, prevent relapses, and improve long-term outcomes. Early intervention has been shown to significantly improve treatment outcomes, especially when initiated during the first episode of psychosis [10]. Cognitive symptoms, such as impairments in memory and executive function, are particularly difficult to treat because they stem from abnormalities not sufficiently addressed by standard dopamine-targeting antipsychotics [21].

Evidence suggests that the most effective pharmacological treatments involve a combination of antipsychotics. The use of second-generation (atypical) antipsychotics is preferred due to their more favorable side effect profiles. Commonly prescribed medications include risperidone, aripiprazole, and quetiapine [22]. Despite the effectiveness of these medications, approximately 30% of individuals with schizophrenia are considered treatment-resistant; in these cases, clozapine is the most effective option due to its superior efficacy in reducing persistent positive symptoms, even when other antipsychotics fail [23]. Electroconvulsive therapy (ECT), controlled electrical stimulation to the brain, is being explored as an adjunctive treatment, particularly for individuals with treatment-resistant schizophrenia. ECT has demonstrated some efficacy in reducing cognitive impairments when combined with pharmacotherapy [24].

Psychosocial interventions can help target cognitive and functional deficits not adequately managed by medication alone. These include cognitive behavioral therapy (CBT), helping individuals challenge distorted thinking patterns, family psychoeducation, informing and supporting families' understanding, and social skills training, which improves communication and social behaviors. Family-based interventions are particularly effective in reducing relapse rates when delivered consistently over extended periods. Additionally, psychosocial treatments have been shown to enhance treatment adherence, social functioning, and overall psychological well-being [25]. However, significant barriers persist in accessing treatment, including nonadherence to treatment, limited availability of mental health services, high treatment costs, and inadequate psychosocial support. Addressing these systemic obstacles is essential for improving treatment accessibility and effectiveness for individuals with schizophrenia [26].

Current Research

Despite significant advances, much remains to be understood about the etiology, progression, and optimal treatment of schizophrenia. Modern research continues to explore the neurodevelopmental and genetic underpinnings of the disorder. Large-scale genome-wide association studies have identified genetic variants implicated in key neurological processes, including synaptic plasticity, neurotransmitter signaling, and immune system function [12, 27].

A major area of unmet need is the treatment of negative and cognitive symptoms, which are often the most debilitating and least responsive to existing medications. As a result, considerable research is directed toward identifying novel pharmacological targets, including trace amine-associated receptor 1 (TAAR1) agonists, compounds that modulate neurotransmitter systems [28], anti-inflammatory agents [29], and cholinergic neurotransmission agonists [30]. These emerging therapies aim to address symptom domains that significantly impair functional outcomes and quality of life. Techniques such as electroconvulsive therapy (ECT) are being explored as supplemental treatments for treatment-resistant individuals [25].

Additionally, adjunctive interventions such as aerobic exercise programs are being explored for their potential to improve cognitive function, mood regulation, and overall well-being [31]. The role of the gut microbiome in the development and modulation of schizophrenia symptoms is also under active investigation, with emerging evidence

suggesting links between microbial composition, neuroinflammation, and cognitive functioning [32]. These lifestyle-based strategies may enhance the effects of standard treatments and offer a more holistic approach to long-term care.

Conclusion

Schizophrenia remains one of the most complex and challenging psychiatric disorders, with a substantial impact on individuals, caregivers, and communities. Although current treatments help manage positive and negative symptoms, cognitive impairments persist as significant issues to full recovery. Early intervention, combined with pharmacological and psychosocial treatment, results in the most favorable outcomes. Ongoing research into new therapeutic targets, neurobiological mechanisms, and environmental causes provides hope for more effective symptom management strategies. Continued systemic efforts are essential to reduce barriers to treatment and improve the quality of life for individuals living with schizophrenia.

List of Abbreviations

CBT: cognitive behavioral therapy
DSM-5: diagnostic and statistical manual of mental disorders, fifth edition
ECT: electroconvulsive therapy
TAAR1: trace amine-associated receptor 1
URNCST: undergraduate research in natural and clinical science and technology

Conflicts of Interest

The author(s) declare that they have no conflict of interests.

Authors' Contributions

MN: made contributions to the design of the study, collected and analysed data, drafted the manuscript, and gave final approval of the version to be published.

Acknowledgements

I acknowledge the endless support of my parents, Martha Dominguez Morales and Nasir Navidpour, and my partner, Bryce Jamison, throughout the development of this work. I acknowledge the use of ChatGPT, GPT-4 in the writing of this entry.

Funding

The development of this encyclopedia entry was not funded.

References

[1] Hany M, Rehman B, Azhar Y, Chapman J. Schizophrenia [Internet]. NIH.gov. StatPearls Publishing; 2024. Available from: https://www.ncbi.nlm.nih.gov/books/NBK539864/
[2] Ruby E, Polito S, McMahon K, Gorovitz M, Corcoran C, Malaspina D. Pathways associating childhood trauma to the neurobiology of schizophrenia: a literature review with theoretical and clinical implications. Frontiers in Psychology and Behavioral Sci. 2014;3(1):1–17. Available from: https://doi.org/10.3389/fpsyg.2014.00017
[3] National Institute of Mental Health. Schizophrenia [Internet]. National Institute of Mental Health. National Institute of Mental Health; 2024. Available from: https://www.nimh.nih.gov/health/topics/schizophrenia
[4] Jablensky A. The diagnostic concept of schizophrenia: Its history, evolution, and future prospects. Dialogues in Clinical Neuroscience. 2010 Sept 30;12(3):271–87. Available from: https://doi.org/10.31887/DCNS.2010.12.3/ajablensky
[5] Angane A. The divine madness: A history of schizophrenia. Annals of Indian Psychiatry. 2017;1(2):133. Available from: https://doi.org/10.4103/aip.aip_31_17
[6] Schizophrenia [Internet]. World Health Organization; [cited 2025 Nov 11]. Available from: https://www.who.int/news-room/fact-sheets/detail/schizophrenia
[7] Solmi, M., Seitidis, G., Mavridis, D. et al. Incidence, prevalence, and global burden of schizophrenia - data, with critical appraisal, from the Global Burden of Disease (GBD) 2019. Molecular Psychiatry 28, 5319–5327 (2023). Available from: https://doi.org/10.1038/s41380-023-02138-4
[8] Li R, Ma X, Wang G, Yang J, Wang C. Why sex differences in schizophrenia? Journal of Translational Neuroscience (Beijing). 2016;1(1):37–42. PMID: 29152382
[9] Correll CU, Solmi M, Croatto G, Schneider LK, Rohani-Montez SC, Fairley L, et al. Mortality in people with schizophrenia: A systematic review and meta-analysis of relative risk and aggravating or attenuating factors. World Psychiatry. 2022 May 7;21(2):248–71. Available from: https://doi.org/10.1002/wps.20994
[10] Schizophrenia Treatment [Internet]. NHS; [cited 2025 Jul 26]. Available from: https://www.nhs.uk/mental-health/conditions/schizophrenia/treatment/
[11] Pruessner M, Cullen AE, Aas M, Walker EF. The neural diathesis-stress model of schizophrenia revisited: An update on recent findings considering illness stage and neurobiological and methodological complexities. Neuroscience & Biobehavioral Reviews. 2016 Dec 12;73:191–218. Available from: https://doi.org/10.1016/j.neubiorev.2016.12.013

[12] Trifu S, Kohn B, Vlasie A, Patrichi B-E. Genetics of schizophrenia (review). Experimental and Therapeutic Medicine. 2020 Jul 7.Available from: https://doi.org/10.3892/etm.2020.8973
[13] Biological insights from 108 schizophrenia-associated genetic loci. Nature. 2014 Jul;511(7510):421–7. Available from: https://doi.org/10.1038/nature13595
[14] Shen C-L, Tsai S-J, Lin C-P, Yang AC. Progressive brain abnormalities in schizophrenia across different illness periods: A structural and functional MRI study. Schizophrenia. 2023 Jan 5;9(1). Available from: https://doi.org/10.1038/s41537-022-00328-7
[15] Svancer P, Spaniel F. Brain ventricular volume changes in schizophrenia. A narrative review. Neuroscience Letters. 2021 Aug;759:136065. Available from: https://doi.org/10.1016/j.neulet.2021.136065
[16] Jenkins TA. Perinatal complications and schizophrenia: Involvement of the immune system. Frontiers in Neuroscience. 2013;7. Available from: https://doi.org/10.3389/fnins.2013.00110
[17] ICD-11 [Internet]. World Health Organization; [cited 2025 Jul 27]. Available from: https://icd.who.int/
[18] Murray RM, Englund A, Abi-Dargham A, Lewis DA, Di Forti M, Davies C, et al. Cannabis-associated psychosis: Neural substrate and clinical impact. Neuropharmacology. 2017 Sept; 124:89–104. Available from: doi: https://doi.org/10.1016/j.neuropharm.2017.06.018
[19] American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-5 [Internet]. 5th ed. Arlington (VA): American Psychiatric Publishing; 2013 [cited 2025 Jul 25]. Available from: https://dsm.psychiatryonline.org/
[20] Bassett AS, Bury A, Honer WG. Testing Liddle's three-syndrome model in families with schizophrenia. Schizophrenia Research. 1994 Jun;12(3):213–21. Available from: https://doi.org/10.1016/0920-9964(94)90031-0
[21] McCutcheon, R.A., Keefe, R.S.E. & McGuire, P.K. Cognitive impairment in schizophrenia: aetiology, pathophysiology, and treatment. Molecular Psychiatry 28, 1902–1918 (2023). Available from: https://doi.org/10.1038/s41380-023-01949-9
[22] Willner K, Vasan S, Patel P, Abdijadid S. Atypical Antipsychotic Agents. In: StatPearls. StatPearls Publishing, Treasure Island (FL); 2025. PMID: 28846323.
[23] Raguraman J, Vijay Sagar Kj, Chandrasekaran R. Effectiveness of clozapine in treatment-resistant schizophrenia. Indian Journal of Psychiatry. 2005;47(2):102. Available from: https://doi.org/10.4103/0019-5545.55955
[24] Petrides G, Malur C, Braga RJ, Bailine SH, Schooler NR, Malhotra AK, et al. Electroconvulsive therapy augmentation in clozapine-resistant schizophrenia: A prospective, randomized study. American Journal of Psychiatry. 2015;172(1):52–8. Available from: https://doi.org/10.1176/appi.ajp.2014.13060787
[25] Barlati S, Nibbio G, Vita A. Evidence-based psychosocial interventions in schizophrenia: A critical review. Current Opinion in Psychiatry. 2024;37(3):131–9. Available from: https://doi.org/10.1097/yco.0000000000000925
[26] Higashi K, Medic G, Littlewood KJ, Diez T, Granström O, De Hert M. Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review. Therapeutic Advances in Psychopharmacology. 2013;3(4):200-218. Available from: https://doi.org/10.1177/2045125312474019
[27] Owen MJ, Legge SE, Rees E, Walters JT, O'Donovan MC. Genomic findings in schizophrenia and their implications. Molecular Psychiatry. 2023 Sept;28(9):3638–47. Available from: https://doi.org/10.1038/s41380-023-02293-8
[28] Dedic N, Dworak H, Zeni C, Rutigliano G, Howes OD. Therapeutic potential of TAAR1 agonists in schizophrenia: Evidence from preclinical models and clinical studies. International Journal of Molecular Sciences. 2021 Dec 7;22(24):13185. Available from: https://doi.org/10.3390/ijms222413185
[29] Weickert TW, Jacomb I, Lenroot R, Lappin J, Weinberg D, Brooks WS, et al. Adjunctive canakinumab reduces peripheral inflammation markers and improves positive symptoms in people with schizophrenia and inflammation: A randomized control trial. Brain, Behavior, and Immunity. 2024 Jan;115:191–200. Available from: https://doi.org/10.1016/j.bbi.2023.10.012
[30] Dudzik P, Lustyk K, Pytka K. Beyond dopamine: Novel strategies for schizophrenia treatment. Medicinal Research Reviews. 2024 Apr 23;44(5):2307–30. Available from: https://doi.org/10.1002/med.22042
[31] Guo J, Liu K, Liao Y, Qin Y, Yue W. Efficacy and feasibility of aerobic exercise interventions as an adjunctive treatment for patients with schizophrenia: A meta-analysis. Schizophrenia. 2024 Jan 2;10(1). Available from: https://doi.org/10.1017/S0033291724001867
[32] Vasileva SS, Yang Y, Baker A, Siskind D, Gratten J, Eyles D. Associations of the gut microbiome with treatment resistance in schizophrenia. JAMA Psychiatry. 2024 Mar 1;81(3):292. Available from: https://doi.org/10.1001/jamapsychiatry.2023.5371
[33] ChatGPT [Internet]. OpenAI; 2023 [cited 2025 Jul 26]. Available from: https://chat.openai.com/

Article Information
Managing Editor: Jeremy Y. Ng
Peer Reviewers: Milica Pavlovic, Chun Ju Liang
Article Dates: Received Aug 1 25; Accepted Nov 22 25; Published Jan 15 26

Citation
Please cite this article as follows:
Navidpour M. Schizophrenia. URNCST Journal. 2026 Jan 15:10(1). https://urncst.com/index.php/urncst/article/view/941
DOI Link: https://doi.org/10.26685/urncst.941